JP2021529780A5 - - Google Patents

Info

Publication number
JP2021529780A5
JP2021529780A5 JP2020573365A JP2020573365A JP2021529780A5 JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5 JP 2020573365 A JP2020573365 A JP 2020573365A JP 2020573365 A JP2020573365 A JP 2020573365A JP 2021529780 A5 JP2021529780 A5 JP 2021529780A5
Authority
JP
Japan
Prior art keywords
alkyl
syndrome
disease
aryl
autoimmune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529780A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040357 external-priority patent/WO2020010118A1/en
Publication of JP2021529780A publication Critical patent/JP2021529780A/ja
Publication of JP2021529780A5 publication Critical patent/JP2021529780A5/ja
Pending legal-status Critical Current

Links

JP2020573365A 2018-07-03 2019-07-02 Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 Pending JP2021529780A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862693879P 2018-07-03 2018-07-03
US201862693886P 2018-07-03 2018-07-03
US62/693,879 2018-07-03
US62/693,886 2018-07-03
US201862702602P 2018-07-24 2018-07-24
US201862702621P 2018-07-24 2018-07-24
US62/702,621 2018-07-24
US62/702,602 2018-07-24
PCT/US2019/040357 WO2020010118A1 (en) 2018-07-03 2019-07-02 Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist

Publications (2)

Publication Number Publication Date
JP2021529780A JP2021529780A (ja) 2021-11-04
JP2021529780A5 true JP2021529780A5 (cg-RX-API-DMAC10.html) 2022-07-11

Family

ID=67441657

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020573365A Pending JP2021529780A (ja) 2018-07-03 2019-07-02 Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法

Country Status (9)

Country Link
US (1) US20220339169A1 (cg-RX-API-DMAC10.html)
EP (1) EP3817737A1 (cg-RX-API-DMAC10.html)
JP (1) JP2021529780A (cg-RX-API-DMAC10.html)
KR (1) KR20210030947A (cg-RX-API-DMAC10.html)
CN (1) CN112654350A (cg-RX-API-DMAC10.html)
AU (1) AU2019299444A1 (cg-RX-API-DMAC10.html)
CA (1) CA3103664A1 (cg-RX-API-DMAC10.html)
IL (1) IL279889A (cg-RX-API-DMAC10.html)
WO (1) WO2020010118A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11370763B2 (en) * 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US11623922B2 (en) 2017-10-03 2023-04-11 Inflazome Limited Compounds
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MX2021000660A (es) 2018-07-20 2021-03-25 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1.
WO2021002887A1 (en) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
WO2022047758A1 (en) * 2020-09-05 2022-03-10 Zhejiang University Genetical disease modelling using mammals having nlrp3 mutation
CN117279903A (zh) * 2021-02-10 2023-12-22 杭州英创医药科技有限公司 作为nlrp3抑制剂的化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116917282B (zh) * 2021-05-10 2026-08-11 康百达(四川)生物医药科技有限公司 酰胺衍生物及其应用
CN117693340A (zh) * 2021-07-23 2024-03-12 诺华股份有限公司 Nlrp3抑制剂治疗骨关节炎的给药方案
EP4396349A4 (en) * 2021-09-02 2025-10-22 Molecular Axiom Llc COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION
WO2023098613A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的制备方法
US20230416412A1 (en) * 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
CN119816304A (zh) * 2022-07-27 2025-04-11 诺华股份有限公司 Nlrp3抑制剂的给药方案
CN116459260A (zh) 2023-04-28 2023-07-21 中国人民解放军空军军医大学 一种特异性靶向nlrp3炎症小体抑制剂的用途
WO2024248286A1 (ko) * 2023-06-01 2024-12-05 한양대학교 에리카산학협력단 결핵균 유래 폴리펩타이드를 포함하는 암 치료용 약학 조성물
WO2024248287A1 (ko) * 2023-06-01 2024-12-05 한양대학교 에리카산학협력단 결핵균 유래 폴리펩타이드를 포함하는 염증성 질환 치료용 약학 조성물
TW202513060A (zh) * 2023-09-29 2025-04-01 瑞士商諾華公司 用於降低心血管疾病的風險之nlrp3抑制劑
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
CA2085297A1 (en) * 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
SG146624A1 (en) * 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
US20180008629A1 (en) * 2015-01-29 2018-01-11 Yale University Compositions and Methods for Treating NLRP3 Inflammasome-Related Diseases and Disorders
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
WO2017079352A2 (en) * 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
WO2017123672A1 (en) * 2016-01-12 2017-07-20 Lawrence Chan Combination treatment for inflammatory diseases
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CN110914256A (zh) * 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
US11370763B2 (en) * 2017-07-24 2022-06-28 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7412328B2 (ja) * 2017-07-24 2024-01-12 ノバルティス アーゲー Nlrp活性に関連する状態を治療するための化合物及び組成物
US20200399242A1 (en) * 2018-03-02 2020-12-24 Inflazome Limited Novel compounds

Similar Documents

Publication Publication Date Title
CN116583508B (zh) 一系列哌啶取代的苯酸类化合物及其应用
JP7551060B2 (ja) プログラム可能なポリマー薬
JP7603918B2 (ja) プログラム可能なポリマー薬
JP7618137B2 (ja) プログラム可能なポリマー薬
CA3103664A1 (en) Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a nlrp3 antagonist
US12486278B2 (en) MASP-2 inhibitors and methods of use
JP7721142B2 (ja) Masp-2阻害剤および使用方法
JP2022505525A5 (cg-RX-API-DMAC10.html)
KR20250007056A (ko) 악성 종양 치료용 제제 및 조성물
US12110288B2 (en) MASP-2 inhibitors and methods of use
AU2023266363A1 (en) MASP-2 inhibitors and methods of use
JP2019506380A5 (cg-RX-API-DMAC10.html)
AU2013227024A1 (en) Novel piperidine compound or salt thereof
RU2012144844A (ru) Комплексные соединения железа(iii) для лечения и профилактики симптомов железодефицита и железодефицитной анемии
JP7058322B2 (ja) 細菌感染症を治療するための化合物および方法
JP2025521156A (ja) Dnaポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用
JP2023509442A5 (cg-RX-API-DMAC10.html)
US20240336606A1 (en) Substituted benzo or pyridopyrimidine amine inhibitor, preparation method therefor, and application thereof
WO2024140923A1 (zh) Prmt5-mta抑制剂
AU2018453128B2 (en) Pan-KIT kinase inhibitor having quinoline structure and application thereof
JP7731151B2 (ja) トリアゾロピラジン系化合物及びその用途
US20250263383A1 (en) Novel inhibitors of guanosine monophosphate synthetase as therapeutic agents
WO2025166260A1 (en) Amide substituted tricyclic guanidino compounds as prmt5 inhibitors
WO2016050201A1 (zh) 高选择性取代嘧啶类pi3k抑制剂
TWI627955B (zh) β-咔啉生物鹼於抑制黃嘌呤氧化酶活性之用途